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Abstract
H1N1 influenza causes substantial seasonal illness and was the subtype of the 2009 in-
fluenza pandemic. Precise measures of antigenic distance between the vaccine and circulating
virus strains help researchers design influenza vaccines with high vaccine effectiveness. We here
introduce a sequence-based method to predict vaccine effectiveness in humans. Historical epi-
demiological data show that this sequence-based method is as predictive of vaccine effectiveness
as hemagglutination inhibition (HI) assay data from ferret animal model studies. Interestingly,
the expected vaccine effectiveness is greater against H1N1 than H3N2, suggesting a stronger
immune response against H1N1 than H3N2. The evolution rate of hemagglutinin in H1N1
is also shown to be greater than that in H3N2, presumably due to greater immune selection
pressure.
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1 Introduction
The annual trivalent vaccine for influenza contains one H3N2 strain, one H1N1 strain, and one
influenza B strain. This vaccine is currently the primary tool to prevent influenza infection and to
control influenza epidemics. Due to the fast evolution of the influenza virus, the components of the
influenza vaccine are changed for many flu seasons. Even though the vaccine is usually redesigned
to match closely the newly evolved influenza virus strains, there occasionally has been a suboptimal
match between vaccine and virus. Partly for this reason, vaccine effectiveness has varied in different
years. The desire to have a vaccine with high effectiveness makes the prediction of the circulating
influenza strain for the next influenza season a key step in vaccine design. A goal of the WHO is
to recommend vaccine strains for the next flu season that will have the smallest antigenic distances
to the dominant circulating strains in the next flu season, which often means using the dominant
circulating strains in the current flu season as a reference.
A variety of distance measures have been developed to evaluate the degree of match between the
vaccine strain and the dominant circulating strain. The hemagglutinin protein (HA) of influenza
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is primarily focused upon for this distance calculation since hemagglutinin is the dominant antigen
for protective human antibodies and exhibits the highest evolutionary rate among all the influenza
genes (Rambaut et al. 2008). A widely used definition of antigenic distance is calculated from
hemagglutination inhibition data from ferret animal model studies. To compare a pair of strains,
a 2-by-2 HI titer matrix is built, and the antigenic distance is extracted from this matrix. This
distance can be further refined by a dimensional projection technique termed antigenic cartography
(Smith et al. 2004). The mathematical basis of antigenic cartography is the dimension reduction of
the shape space in which each point represents an influenza virus strain and the distance between
a pair of points represents the antigenic distance between the corresponding strains. Note that
antigenic cartography does not yield the distance data itself, but assesses the distance between the
given vaccine strain and dominant circulating strain by globally considering the effect of all the
strains and the antigenic distances among them. In the original literature of antigenic cartography
(Smith et al. 2004), hemagglutination inhibition data were the input of the antigenic cartography
algorithm that obtains the final results of distances. Antigenic distances can also be defined by
the amino acid sequences of the strains using computer-aided methods, in which the fraction of
substituted amino acid in the dominant hemagglutinin epitope bound by antibody is defined by
pepitope as a sequence-based antigenic distance measure (Deem and Pan 2009; Gupta et al. 2006;
Pan and Deem 2009). The amino acid sequences are downloaded from databases and processed
to obtain these distance measures. The pepitope sequence-based method has been shown to be an
effective antigenic distance measure between two strains of H3N2 (Deem and Lee 2003; Gupta et al.
2006; Pan and Deem 2009). To be clear, antigenic distance is a quantity that should define difference
of viral strains, as determined by the human immune system. Ferret HI data are not the only or
even the best measure of antigenic distances.
The vaccine effectiveness, which varies from year to year, correlates with the antigenic distance
between the vaccine strain and the dominant circulating strain. Thus the vaccine effectiveness
can be predicted by calculating the antigenic distance. Such a priori estimation of the vaccine
effectiveness guides health authorities to determine the appropriate strain for the vaccine component
for the coming flu season. For H3N2 influenza, the pepitope method offers a prediction of vaccine
effectiveness that has a higher correlation coefficient with vaccine effectiveness in humans than
do distances derived by other methods (Gupta et al. 2006; Pan and Deem 2009). In this paper,
we develop the pepitope method for H1N1 influenza. In Materials and Methods we describe the
epidemiological data used to calculate vaccine effectiveness and the animal model or sequence data
used to calculate antigenic distance. In Results we show the correlation of antigenic distance with
vaccine effectiveness. We discuss the results in the Discussion.
2 Materials and Methods
2.1 Identities of Vaccine Strains and Dominant Circulating Strains
The vaccine strain selection by WHO in each year follows a standard procedure. The vaccine
strains are reviewed every year and are usually changed every two to three years. We used the
H1N1 vaccine strains and H1N1 dominant circulating strains in the epidemiological literature that
provided vaccine effectiveness data used in this study.
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2.2 Estimation of Vaccine Effectiveness
The H1N1 vaccine effectiveness is gathered from epidemiological literature regarding the influenza-
like illness rate of unvaccinated (u) and vaccinated people (v). Vaccine effectiveness can be described
by the following definition:
vaccine effectiveness =
u− v
u
. (1)
To calculate vaccine effectiveness and its standard error, we let Nu and Nv denote the number
of subjects in the unvaccinated and vaccinated group, nu and nv denote the number of illness in
the unvaccinated and vaccinated group, respectively. The values and the standard errors of u, v,
and vaccine effectiveness are
u = nu/Nu (2)
v = nv/Nv (3)
VE =
u− v
u
=
nuNv − nvNu
nuNv
(4)
σu =
√
u (1− u)
Nu
(5)
σv =
√
v (1− v)
Nv
(6)
σVE =
( v
u
)√(σv
v
)2
+
(σu
u
)2
=
√(
1
u
)2
σ2v +
( v
u2
)2
σ2u. (7)
If the vaccine effectiveness is averaged from N studies, σ2VE =
(∑
i σ
2
VEi
)
/N2 where σVEi is the
standard error of the i–th study.
Compared to H3N2, subtype H1N1 viruses were dominant in fewer years. Based on the pro-
portions of samples of H3N2, H1N1, and influenza B collected in each year during 1977–2009,
widespread H1N1 circulation was observed in approximately 10 seasons. Epidemiological studies
on vaccine effectiveness were absent for some years when H1N1 circulated. Additionally, we used
the criteria listed below to filter all available literature.
To ensure that the vaccine effectiveness we collected from the literature is for H1N1, the seasons
and the geographic regions of the epidemiological studies in the literature were compared with the
influenza activity information in WHO Weekly Epidemiological Records to confirm that those re-
gions were dominated by H1N1 in those seasons. Subjects were restricted to 18–64 year old healthy
adult humans to avoid effects of an underdeveloped immune system in children or of immunosenes-
cence in senior people. If more than one measure of vaccine effectiveness was collected for the same
season, they were averaged to minimize the statistical noise.
In order to minimize the effect on vaccine effectiveness from co-circulating subtypes such as
H3N2, only the epidemiological data collected in the regions and in the flu seasons in which the
H1N1 subtype was dominant were applied to calculate the vaccine effectiveness in this study. The
seasons in which the H1N1 subtype was dominant were reported by the literature on H1N1 vaccine
effectiveness. The studies cited in Table 2 for the calculation of vaccine effectiveness gave the
subtype of the predominant epidemic virus as well as of the virus sampled from the subjects with
influenza-like illness (ILI). In addition, the dominance of H1N1 subtype is also available in the CDC
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Morbidity and Mortality Weekly Reports and the WHO Weekly Epidemiological Record. For the
data in Table 2, the dominance of H1N1 subtype was shown in these references.
The vaccine effectiveness collected from various flu seasons and regions were measured with stan-
dard errors. Biases in the vaccine effectiveness are due to the complexity of the vaccine effectiveness
measurement, including the character of the human population studied, such as age, immune his-
tory, and health condition; the influence of co-circulating H3N2 influenza strains; the character of
the vaccine distributed, such as live attenuated virus vaccine, inactivated split-virus vaccine pro-
duced by virion disassembly, or subunit vaccine only containing hemagglutinin and neuraminidase;
the method of epidemiological measurement of influenza infection, such as virus detection, con-
firmed symptomatic influenza, or influenza-like illness (ILI); the design of the experiment, such
as natural infection or experimental challenge study; and the progression of the epidemic in the
population under study. These biases are thus inevitable with current technology. Here, we applied
the following methods to minimize biases in the vaccine effectiveness data. Subjects in the studies
were confined to 18–64 years old healthy adult humans to preclude the interference of the feeble
immune system in children or in senior people, because variation in the capability of the immune
system is a determinant of the vaccine effectiveness given the same pair of vaccine strain and dom-
inant circulating strain. Only epidemiological studies in the season and the region in which H1N1
subtype was dominant were used to obtain the vaccine effectiveness data. The vaccine involved in
the referred studies is an inactivated vaccine. Other types such as cold-adapted nasal spray vaccine
were excluded. The epidemiological measurement of infection in all the referred studies used ILI
as the criterion. Not all studies designed the experiment as a challenge study. We assume that
the epidemic propagates in the population in a similar way in each season. These criteria are used
to filter the available references and to obtain vaccine effectiveness data with minimum bias. The
standard errors of the data are presented here. These criteria reduced the number of practical
references for each season. Our metaanalysis considered 50 peer-reviewed papers, all we could find
in the literature. We list the ones that satisfy our selection criteria for each of the years, typically
1–3 per year.
2.3 Antigenic Distance Measured By Sequence Data
Figure 1 shows the HA1 domain with five epitopes of the H1 subtype hemagglutinin. As the
improvement of a previous definition of H1 epitopes (Caton et al. 1982), these five H1 epitopes
are recognized by host antibodies and are identified by mapping the well-defined epitopes in H3
hemagglutinin (Macken et al. 2001; Wiley et al. 1981) to H1 hemagglutinin and using sequence
entropy to find additional sites under selection (Deem and Pan 2009).
The antigenic distance between the vaccine strain and the dominant circulating strain is the
input for the vaccine effectiveness prediction. The fraction of mutated amino acids in the epitope
region of HA, or the p-value, is an antigenic distance measure to quantify the similarity between
two strains (Gupta et al. 2006). One p-value is calculated for each H1 epitope
p-value =
number of mutations in the epitope
number of amino acids in the epitope
. (8)
The pepitope is defined as the maximum of five p-values for the five epitopes, and the dominant
epitope is defined as the corresponding epitope. This definition, i.e. assumption, has lead for H3N2
to vaccine effectiveness predictions that correlate with those observed (Gupta et al. 2006).
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Table 1: HI table with two strains and four HI titers.
Ferret antisera Ferret antisera
against Strain 1 against Strain 2
Strain 1 H11 H12
Strain 2 H21 H22
Another sequence-based antigenic distance measure uses the fraction of mutated amino acid in
all the five epitopes
pall-epitope =
number of mutations in all the five epitopes
number of amino acids in all the five epitopes
. (9)
As an alternative to pepitope and pall-epitope, psequence is also used with the definition
psequence =
number of mutations in the HA1 domain of hemagglutinin
total number of amino acids in the HA1 domain of hemagglutinin
. (10)
2.4 Antigenic Distance Measured by Hemagglutination Inhibition
The animal model method to determine the distance between the vaccine strain and the dominant
circulating strain employs the HI assay to give the HI table. See Table 1: Here Hij , i, j = 1, 2
are four HI titers measuring the capability of antibody j to inhibit hemagglutinin i. Note that in
reality, health authorities including WHO and CDC provide HI tables with at least eight antisera to
evaluate the antigenic distance between candidate vaccine strains and dominant circulating strain.
These HI tables are mathematically equivalent to several 2× 2 HI tables each of which defines the
antigenic distance between one pair of strains in the original HI table. For each pair of strains, we
picked up four entries determined by the identities of these two strains and the two corresponding
antisera from the original HI table. The 2×2 HI tables in this manuscript are used to elaborate the
formulae for d1 and d2. In this context Strain 1 is the vaccine strain and Strain 2 is the dominant
circulating strain. Two distance measures have been derived from these four HI titers in the HI
table (Lee and Chen 2004; Smith et al. 1999):
d1 = log2
(
H11
H21
)
(11)
d2 =
√
H11H22
H21H12
. (12)
Note that antigenic cartography is carried out on the asymmetrical distance, d1 (Smith et al. 2004).
When the vaccine strain and the dominant circulating strain in one season were not identical, we
searched the literature for the HI tables with these two strains. The d1 and d2 values were averaged
if multiple HI tables were found for one season.
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Figure 1: HA1 domain of the H1 hemagglutinin in the ribbon format (PDB code: 1RU7). Epitope
A (blue), B (red), C (cyan), D (yellow), and E (red) are space filling. These five H1 epitopes are
the analogs of the well-defined H3 epitopes (Deem and Pan 2009).
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Table 2: Summary of results. Nine pairs of vaccine strains and dominant circulating strains in seven flu seasons in the Northern
hemisphere were collected from literature. The quantities nu, Nu, nv, Nv, pepitope, pall-epitope, psequence, d1, and d2 are defined
in Materials and Methods. Only those seasons when H1N1 virus was dominant in at least one country or region where vaccine
effectiveness data were available were considered. Two different vaccines have occasionally been adopted in different geographic
regions for the same season, in which case two sets of data were added in this table. An asterisk signifies that co-circulating
H3N2 was also found in the same country or region in that season; however, the interference to the final result from H3N2 is
expected to be small, and so the sets of data with a single asterisk were preserved.
Season Vaccine strain Dominant Vaccine nu Nu nv Nv Dominant pepitope pall-epitope psequence d1 d2
Circulating strain‡ effectiveness epitope
(%)
1982–83 A/Brazil/11/78 A/England/333/80 37.0 ± 12.01 48 118 31 1211 A 0.083 0.0311 0.0184 010 1.4110
1983–84 A/Brazil/11/78 A/Victoria/7/83 38.1 ± 10.31–3 30 60 21 671 C 0.121 0.0497 0.0337 1.1311–13 13.6611,13
55 298 46 3002
1986–87 (a) A/Taiwan/1/86 A/Taiwan/1/86 64.8 ± 14.33,4 11 217 13 7234 0 0 0 0 1
1986–87 (b) A/Chile/1/83 A/Taiwan/1/86 18.5 ± 12.15 92 878 75 8785 B 0.318 0.0807 0.0399 412,14–18 24.4814,16–18
1988–89 A/Taiwan/1/86 A/Taiwan/1/86 43.1 ± 10.03,5 119 1125 89 11265 0 0 0 0 1
1995–96 (a) A/Texas/36/91 A/Texas/36/91 60.0 ± 27.86 6 12 2 106 0 0 0 0 1
1995–96 (b)* A/Singapore/6/86 A/Texas/36/91 32.2 ± 5.87 99 652 57 6847 A 0.125 0.0559 0.0307 0.8614,19,20 2.4314,20
176 652 149 6847
2006–07 A/New Caledonia/20/99 A/New Caledonia/20/99 40.5 ± 2.58 1085 230729 1221 4366008 0 0 0 0 1
2007–08* A/Solomon Islands/3/2006 A/Solomon Islands/3/2006 62.8 ± 12.69 94 262 8 609 0 0 0 0 1
‡Multiple strains are circulating in each season, while each strain has a specific proportion in the virus population in a certain
region and season. The strain with the greatest proportion is defined as the dominant circulating strain, which is listed in
this table. The dominant circulating strains in this table were chosen based on the literature on vaccine effectiveness, which
also gave the region where the effectiveness data were collected.
Literature used in the metaanalysis: 1. (Couch et al. 1986); 2. (Keitel et al. 1988); 3. (Couch et al. 1996); 4. (Keitel et al.
1997); 5. (Edwards et al. 1994); 6. (Treanor et al. 1999); 7. (Grotto et al. 1998); 8. (Wang et al. 2009); 9. (Belongia et al.
2008); 10. (Daniels et al. 1985); 11. (Chakraverty et al. 1986); 12. (Smith et al. 1999); 13. (WHO 1984); 14. (Hay et al.
2001); 15. (WHO 1986); 16. (Kendal et al. 1990); 17. (Donatelli et al. 1993); 18. (Brown et al. 1998); 19. (WHO 1992); 20.
(Rimmelzwaan et al. 2001).
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3 Results
We performed a metaanalysis of identities of the vaccine strains and dominant circulating strains,
vaccine effectiveness, and antigenic distances between vaccine strains and dominant circulating
strains measured with the HI assay using ferret antisera. In one season dominated by H1N1,
epidemiological statistics in a certain region reported in literature was used to fix the values of
nu, Nu, nv, Nv, and the mean and standard error of the vaccine effectiveness. HI assay data
in literature are also used to determine antigenic distance d1 and d2 between the vaccine strain
and dominant circulating strain. Results of the metaanalysis are listed in Table 2. Sequence-based
antigenic distances pepitope, pall-epitope, and psequence are calculated from the sequences of the vaccine
strain and dominant circulating strain by equations 8, 9, and 10, respectively. Values of pepitope,
pall-epitope, and psequence in each season dominated by H1N1 are also listed in Table 2.
While the number of data points is limited, a linear relationship exists between vaccine effective-
ness and pepitope by using least squares. Similar to the case for H3N2 influenza (Gupta et al. 2006),
pepitope strongly correlates with H1N1 vaccine effectiveness, with R
2 = 0.68. The fitted model
predicts a vaccine effectiveness of 52.7% when pepitope = 0, and vaccine effectiveness is greater than
zero when pepitope < 0.442. In Figure 2, the fitted trend line is within one standard error of all
data points with pepitope > 0, validating the ability of the pepitope model to predict the vaccine
effectiveness with only the sequences of the vaccine strain and the dominant circulating strain.
Although statistical errors exist in the observed vaccine effectiveness, the collected vaccine ef-
fectiveness data reject the null hypothesis that the vaccine effectiveness is independent of pepitope.
The nine pairs of vaccine strains and dominant circulating strains in Table 2 have five difference
antigenic distances between vaccine strain and dominant circulating strain defined by pepitope. The
nine pairs of strains were thus categorized into group 1–5 with pepitope equal to 0, 0.083, 0.121, 0.125,
and 0.318, respectively, and the average vaccine effectiveness and standard error were calculated for
each group. The vaccine effectiveness differences between these five groups were significant, such
as group 1 and group 4 (p = 0.0079) and group 1 and group 5 (p = 0.0054). Moreover, statistical
analysis shows that the introduction of pepitope is valuable in the selection process of vaccine strains.
The slope of the fit line is significantly smaller than zero (p = 0.0027). Hence the linear model is
able to predict the vaccine effectiveness with the knowledge of pepitope. In other words the non-zero
slope of vaccine effectiveness as a function of pepitope is significant to the level of 0.27%.
Two other sequence-based antigenic distance measures alternative to pepitope are pall-epitope and
psequence. Unlike pepitope, which focuses upon the mutations in the antibody binding regions,
pall-epitope calculates the fraction of mutated amino acids in all the five epitopes, and psequence
calculates the fraction of mutated amino acids in the whole HA1 domain of hemagglutinin. The
psequence measure is also one of the optional distance measures for phylogenetic softwares. In Figure
3, the correlation between H1N1 vaccine effectiveness and pall-epitope has R
2 = 0.70. In Figure 4,
the correlation between H1N1 vaccine effectiveness and psequence has R
2 = 0.66. The predicted 54%
vaccine effectiveness when pall-epitope in Figure 3 and when psequence = 0 in Figure 4 are almost the
same as the 53% predicted by the pepitope method. By contrast pall-epitope and psequence for H3N2
have less impressive correlations with H3N2 vaccine effectiveness (Gupta et al. 2006; Sun et al.
2006), and pall-epitope and psequence are not as effective as pepitope as antigenic distance measures
and vaccine effectiveness predictors for H3N2.
The HI assay and derived distance measures d1 and d2 are still the most widely used mea-
sures by researchers and health authorities to identify newly collected circulating strains. These
methods are used to recommend the vaccine strain for the coming flu season (Cox et al. 2007,
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2003; WHO collaborating center for surveillance and control of influenza 2008), to draw the anti-
genic map (Smith et al. 2004), and to support the phylogenetic data (Cox et al. 2003). Figure 5
and 6 describe the correlation between vaccine effectiveness and antigenic distances d1 and d2 from
the HI assay. A correlation is found in both figures. In the season 1995–96 in Israel, the vaccine
strain is A/Singapore/6/86 (H1N1) and the dominant circulating strain is A/Texas/36/91 (H1N1),
between which the averaged d1 is 0.86. Since the vaccine effectiveness is only 32.2%, its discrepancy
to the corresponding effectiveness 42.5% in the trend line is much larger than one standard error
of vaccine effectiveness. Similarly, the same pair of vaccine strain and dominant circulating strain
introduces a data point further from the trend line if d2 is used as the distance measure. We also
notice that two strains could be antigenically identical as measured with HI assay but antigenically
distinct as measured with pepitope. As shown in Table 2, in the season 1982–1983, the H1N1 vac-
cine strain A/Brazil/11/78 and dominant circulating strain A/England/333/80 presented the anti-
genic distance measured with HI assay d1 = 0 and the sequence-based antigenic distance measure
pepitope = 0.083. The H3N2 vaccine strain and dominant circulating strain showed identical d1 and
d2 values but distinct pepitope values in the seasons 1996–1997 and 2004–2005 (Gupta et al. 2006).
Note that if pepitope is incorporated into the linear models shown in Figure 5 and 6, the R
2 value is
increased. We fit a linear model vaccine effectiveness = α+ β1pepitope+ β2d1 + β3d2 + ǫ in which ǫ
is an error term. The fitted model is vaccine effectiveness = 0.54− 2.179pepitope+0.068d1+0.003d2
with R2 = 0.72.
4 Discussion
4.1 Verification of the pepitope Model
Originally the pepitope model was implemented for the H3N2 virus, where pepitope correlates with
H3N2 vaccine effectiveness with a significantly largerR2 than do pall-epitope and psequence (Gupta et al.
2006; Sun et al. 2006). In the case of H1N1, the advantage of pepitope over pall-epitope and psequence
is not as remarkable as for H3N2. We speculate that antibodies against the H3N2 virus may bind
to a small fixed region on the surface of H3 hemagglutinin while antibodies against the H1N1
virus may have multiple binding regions available. In other words, we speculate that the dominant
epitope in H3 hemagglutinin may contribute substantially to the escape of the H3N2 virus from
host antibodies, while escape mutations may occur in the dominant epitope as well as perhaps the
subdominant epitopes of H1 hemagglutinin. Our speculation comes from the fact that the epitope
region in H1N1 contains more amino acid positions than does that in H3N2 (Deem and Pan 2009).
Two recent epidemiological studies (Centers for Disease Control and Prevention (CDC) 2009a;
Skowronski et al. 2010) present further support of the pepitope model. Before the emergence of the
H1N1 pandemic flu in April 2009, the 2008–2009 flu season was dominated by subtype H1N1 sea-
sonal flu. Both the dominant circulating strain and the vaccine strain in the 2008–2009 season were
A/Brisbane/57/2007 (H1N1) (Centers for Disease Control and Prevention (CDC) 2009d). The ob-
served vaccine effectiveness against seasonal flu was 44% (95% CI: 33% to 59%) (Skowronski et al.
2010). The pepitope model predicts the vaccine effectiveness as 53%, which falls into the 95% CI of
the reported vaccine effectiveness.
After April 2009, a new peak of influenza activity emerged. The dominant circulating strain in
this period was the pandemic H1N1 strain A/California/7/2009 (Centers for Disease Control and Prevention (CDC)
2009b,c). The reported effectiveness of the 2008–2009 seasonal flu vaccine against the H1N1
pandemic flu was −50% to −150% (Skowronski et al. 2010) and −10% (95% CI: −43% to 15%)
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Figure 2: Vaccine effectiveness for influenza-like illness correlates with pepitope, R
2 = 0.68 (solid
line). Data from Table 2. The trend line quantifies vaccine effectiveness as a decreasing linear
function of pepitope. Vaccine effectiveness = −1.19 pepitope + 0.53. Also shown is the vaccine
effectiveness to H3N2 (dashed line) (Gupta et al. 2006).
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Figure 3: Vaccine effectiveness for influenza-like illness correlates with pall-epitope with R
2 = 0.70.
Data from Table 2. The trend line quantifies vaccine effectiveness as a decreasing linear function
of pall-epitope. Vaccine effectiveness = −4.16 pall-epitope + 0.54.
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Figure 4: Vaccine effectiveness for influenza-like illness correlates with psequence with R
2 = 0.66.
Data from Table 2. The trend line quantifies vaccine effectiveness as a decreasing linear function
of psequence. Vaccine effectiveness = −7.37 psequence + 0.54.
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Figure 5: The correlation with R2 = 0.53 between vaccine effectiveness for influenza-like illness and
d1, the antigenic distance defined by HI assay using ferret antisera. Data from Table 2. The d1
values were averaged if multiple HI assay experimental data were found. The trend line quantifies
vaccine effectiveness as a decreasing linear function of d1. Vaccine effectiveness = −0.085 d1+0.50.
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Figure 6: The correlation with R2 = 0.46 between vaccine effectiveness for influenza-like illness and
d2, the antigenic distance defined by HI assay using ferret antisera. Data from Table 2. The d2
values were averaged if multiple HI assay experimental data were found. The trend line quantifies
vaccine effectiveness as a decreasing linear function of d2. Vaccine effectiveness = −0.013 d2+0.51.
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(Centers for Disease Control and Prevention (CDC) 2009a). The value of pepitope between A/California/7/2009
and A/Brisbane/57/2007 is 0.77 with epitope B as the dominant epitope. The vaccine effectiveness
forecast by the pepitope model is −39%, which agrees with the measured vaccine effectiveness values.
4.2 Comparison of H3N2 and H1N1 Vaccine Effectiveness and Evolution
Rates
The pepitope model has been previously applied to the prediction of H3N2 vaccine effectiveness
(Gupta et al. 2006). The H3N2 vaccine effectiveness with pepitope = 0 is 44.6%, and vaccine effec-
tiveness is greater than zero for pepitope < 0.184 (Gupta et al. 2006). Thus, H1N1 vaccines tend
to have higher vaccine effectiveness compared to H3N2 vaccines, as shown in Figure 2. The com-
parison between H3N2 and H1N1 vaccine effectiveness (Figure 2 versus Figure 2 of (Gupta et al.
2006)) illustrates that H1N1 vaccine has higher effectiveness than the H3N2 vaccine as a function
of pepitope. This observation suggests that the host immune system is more effective at recognizing
and eliminating the H1N1 virus (pepitope = 0), and that humoral cross immunity is stronger for
H1 hemagglutinin (pepitope > 0). This observation also explains why an H3N2 epidemic is usually
a more severe health threat than an H1N1 epidemic. We propose that H1N1 has a longer history
of circulating in the human population, so human immune system may recognize H1N1 more ef-
fectively, and this may be the reason that under stronger immune pressure, the H1N1 virus may
have a higher degree of adaptation to the human host. In the following discussion, we verify this
hypothesis by two facts. First, the H1N1 virus has a larger antigenic diversity than does the H3N2
virus. Second, the H1N1 virus presents higher evolutionary rate in the per dominant season basis.
To compare the antigenic diversities of H1N1 and H3N2, we downloaded from the NCBI database
on 13 August 2009 all the amino acid sequences of H3 hemagglutinin collected in the 18 years with
H3N2 dominant circulating strains (Gupta et al. 2006) and those of H1 hemagglutinin collected in 7
years with H1N1 dominant circulating strains (Table 2). Thus 18 subsets of H3N2 sequences and 7
subsets of H1N1 sequences were formed. The centers of these subsets are the corresponding vaccine
strains in the same season of the circulating virus. The radius of each subset is obtained by the
calculation of pepitope. First, the strains with the top 5% pepitope antigenic distance measure to the
center of each subset were selected, to focus on the extent of viral evolution. Second, the pepitope
between these selected strains and the center were averaged in each year as the radius. Third, the
radii were averaged over all the 18 years for H3N2 and over 7 years for H1N1. That is, the average
radius of the top 5% was calculated in each year. As a result, the average H3N2 subset radius
with the vaccine strains as the centers is 0.211. The average H1N1 radius is 0.520 with the vaccine
strains as the centers. This difference between the H3N2 radius and the H1N1 radius is significant
with the p-value 0.0118 using the Wilcoxon rank-sum test. Consequently, the H1N1 virus has a
larger antigenic diversity in each season compared to the H3N2 virus, as shown in Figure 7.
We also compared the evolutionary rates of H1N1 and H3N2 because evolutionary rate of the
virus is an index of the selection pressure of the virus. The virus undergoes less immune pressure in
a non-dominant season and high immune pressure in a dominant season. It has been noticed that
in H1 and H3 hemagglutinin, the region outside epitopes presents significantly lower evolutionary
rate than do the epitopes (Deem and Pan 2009; Ferguson et al. 2003). This phenomenon indicates
that without immune pressure, the spontaneous evolutionary rates of both H1N1 and H3N2 are
low. Therefore, a higher evolutionary rate of one virus subtype in a dominant season comes from
the higher immune pressure rather than neutral evolution, and we reject the alternative scenario
that the higher evolutionary rate causes a virus subtype to be dominant in one season. So the
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evolutionary rate per dominant season is a natural measure of the virus evolution. Between 1983
to 1997, H3N2 was dominant in 8 of 15 years, and between 1977 to 2000, H1N1 was dominant in
5 of 24 years (Ferguson et al. 2003). Between 1980 to 2000, the HA1 domain of H3 hemagglutinin
has a higher annual evolutionary rate of 3.7× 10−3 nucleotide substitution/site/year than does the
HA1 domain of H1 hemagglutinin, which has the annual evolutionary rate of 1.8× 10−3 nucleotide
substitution/site/year (Ferguson et al. 2003). Measured on a per dominant season basis, however,
the HA1 domain of H1 hemagglutinin evolves faster in its dominant season with the rate of 8.6×10−3
nucleotide substitution/site/dominant season than does the H3 hemagglutinin with the rate of
6.9 × 10−3 nucleotide substitution/site/dominant season. The difference is significant with a p-
value 0.0008. Similarly, between 2000 and 2007, the HA1 domain of H1 hemagglutinin evolves faster
in its dominant season with the rate of 10.2 × 10−3 nucleotide substitution/site/dominant season
than does the H3 hemagglutinin with the rate of 7.4× 10−3 nucleotide substitution/site/dominant
season. The difference is significant with a p-value 0.0005 (Zaraket et al. 2009). Here we have
divided the annual evolutionary rate by the proportion of dominant years for both H1 and H3
hemagglutinin. Even on a short time scale without fixation, H1 hemagglutinin shows a comparable
or higher mutation rate of 9.1 × 10−6 nucleotide substitution/site/day than H3 hemagglutinin of
4.2×10−6 nucleotide substitution/site/day (p = 0.26) (Nobusawa and Sato 2006), probably caused
by the adaptation to the higher immune pressure, at least for some strains. To make this last point,
we have assumed that the mutation rate of the HA gene is the same as that of the NS gene. We
assume that the same polymerase is operating on these two genes, and so the mutation rates are
expected to be the same. The comparisons of evolutionary rates and mutation rates between H3N2
and H1N1 are summarized in Figure 7.
4.3 The pepitope Model as a Supplement to HI Assay
For both H1N1 (this paper) and H3N2 (Gupta et al. 2006), the HI assay correlates less well with
vaccine effectiveness than does pepitope. Collection of HI assay data measuring antigenic distance is
also more time-consuming and more expensive compared to the pepitope model. Many hundreds of
strains are circulating and collected in an average flu season, thus an HI table with tens of thousands
of entries needs to be built to assess the antigenic distance between each pair of strains. With the
high-throughput sequencing technology generating hemagglutinin sequence data, such antigenic
distances are easily measured with the sequence-based antigenic distance measure pepitope, which
correlates to a greater degree with vaccine effectiveness than do the HI data.
The pepitope model is developed to provide researcher and health authorities with a new tool to
quantify antigenic distance and design the vaccine. We do not suggest that pepitope should substitute
for the current HI assay, but rather suggest that pepitope serves as an additional assessment when
selecting vaccine strains. Using pepitope to supplement to HI assay data may allow researchers and
health authorities to more precisely quantify the antigenic distance between dominant circulating
strains and candidate vaccine strains. The adoption of the pepitope theory may also allow researchers
to minimize the cost and the number of ferret experiments and to correct HI assay data in some
situations.
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Figure 7: The comparison between H3N2 (triangle up) and H1N1 (triangle down) in regard to
the antigenic diversity, the evolutionary rate between 1980 and 2000 (left), the evolutionary rate
between 2000 to 2007 (right), and the mutation rate on a short time scale without fixation. The
antigenic diversity is measured with pepitope, the unit of evolutionary rate is 10
−3 nucleotide sub-
stitution/site/year, and the unit of mutation rate is 10−6 nucleotide substitution/site/day.
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1 Humoral Immune System Plays a Major Role in Immunity
to Influenza
The influenza vaccine considered in this study is the trivalent inactivated vaccine (TIV) adminis-
tered by intramuscular injection. The effective components of TIV are hemagglutinin (HA) and
neuraminidase (NA) that noticeably induce the humoral immunity but activate the cellular im-
munity less vigorously (Doherty and Kelso 2008). The other, cold–adaptive trivalent live atten-
uated influenza vaccine (LAIV) is also believed to induce the cellular immunity to a low level
(Doherty and Kelso 2008).
The humoral immunity greatly relies on the antigenic distance between the hemagglutinin of
the vaccine and that of the dominant circulating strain. On the other hand, the cellular immune
system focuses on the highly conserved internal proteins, which are the Matrix protein 1 (M1) and
the nucleoprotein (NP) (Lee et al. 2008). In contrast to the antibodies, CD8+ and CD4+ T cells
show notable cross immunity to a wide variety of strains (Lee et al. 2008). Like the cellular immune
system, the antigen-unspecific innate immune system generates a homogeneous immune reaction
against different influenza strains (Janeway et al. 2005).
For all these reasons ferret antisera, in which antibodies are the major immune component, is
used in the hemagglutination inhibition (HI) assay as the conventional way to measure the antigenic
distance between the vaccine strain and the dominant circulating strain. Therefore, we consider
the antibody rather than the cellular or innate immune system to be the dominant element in our
quantification of antigenic distance between two influenza strains and the key factor for influenza
vaccine effectiveness.
2 Evaluation of Vaccine Effectiveness
By definition, vaccine efficacy is measured by controlled trials with initially susceptible subjects,
while vaccine effectiveness is measured by epidemiological observance of susceptible population
without giving placebo (Kelly et al. 2009). Vaccine efficacy is relatively more idealized than vac-
cine effectiveness, because vaccine effectiveness depends on vaccine efficacy and other environmental
1
factors (Torvaldsen and McIntyre 2002). Although the terms vaccine efficacy and vaccine effective-
ness are interchangeable to some extent (Torvaldsen and McIntyre 2002), we use the term vaccine
effectiveness because factors other than vaccine strain and dominant circulating strain are involved
in the studies used in our metaanalysis. The data source for vaccine effectiveness calculation used
ILI as the primary endpoint, and studies we use contained controlled unvaccinated groups.
The data from four studies require additional clarification. The paper by Edwards et al.
(Edwards et al. 1994) did not provide the retrospectively reported influenza–like illness data prior
to the 1987–88 season, so we use the number of ill subjects presenting for throat culture to calculate
the morbidity rate u and v. Note that in this study, subjects with influenza–like disease were re-
quired to show up for a throat culture, and when characterized by vaccination status the numbers of
such patients is thus a reasonable estimation of the illness rate u and v. Moreover, in other seasons
when both retrospective data and number of presenting ill subjects were available, the vaccine effec-
tiveness calculated from retrospective data and numbers of presenting ill subjects are similar to each
other, especially for subtype H1N1 (Edwards et al. 1994). In Grotto et al.’s study (Grotto et al.
1998) using influenza strains from Israel in the 1995–96 season, the numbers of sampled H1N1 and
H3N2 strains in Israel was 7 and 35, respectively. The samples were collected from six clinics in
December that was in the middle of the influenza season. However, the number of both subjects and
viruses sampled are limited. At the global level with more available data, it was observed that H1N1
and H3N2 were co-circulating with comparable frequencies, and H1N1 virus was found in North
America and part of Eurasia including Israel (Centers for Disease Control and Prevention (CDC)
1996). The proportion of H1N1 in samples during the 1995–96 season in USA ranks #5 in H1N1
proportion since 1977 (Ferguson et al. 2003). In the same season, H3N2 vaccine strain and dom-
inant circulating strain were a perfect match, so the decrease in the overall vaccine effectiveness
is expected to be due to the mismatch in the H1N1 component. Therefore we treat H1N1 here
as a co-circulating strain and take into account the vaccine effectiveness reported in this article
(Grotto et al. 1998). Keitel et al. (Keitel et al. 1997) reported that the dominant circulating strain
in the 1983–84 season was A/Chile/1/83 rather than A/Victoria/7/83 in this table and in other
cited studies. The illness rate u and v are small, and so the standard error of vaccine effectiveness
is 64.8%, which is unacceptable. Thus the use of Keitel et al.’s data for 1983–84 season is not
appropriate to the vaccine effectiveness assessment. The reference by Couch et al. (Couch et al.
1996) did not provide original data nu, Nu, nv, and Nv for the calculation of vaccine effectiveness.
Error bars of vaccine effectiveness in these seasons were calculated with other data sources.
3 Robustness of the pepitope Model
Influenza vaccine effectiveness may depend not only on the antigenic distance between the vaccine
strain and the dominant circulating strain quantified by pepitope, but also on the percentage of
people vaccinated, the time of vaccination in the influenza season, influenza virus transmissibility
and reproduction rate, and individual’s immune history. Thus, development of the public health
system and a greater fraction of the population being vaccinated may result in a trend of both
H1N1 and H3N2 vaccine effectiveness. The statistics of vaccine effectiveness could be biased by
these factors. Nevertheless, greater than 50% of the H1N1 and H3N2 vaccine effectiveness are
explained by pepitope, since R
2 > 1/2. To show that the model of vaccine effectiveness can be
well reduced to a linear form between pepitope and vaccine effectiveness, we calculated the residuals
of linear regression of vaccine effectiveness on pepitope, and performed another linear regression of
these residuals versus year. The trend line of the residuals has a slope of −0.0002/year and the null
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Figure S1: The linear regression with R2 = 0.0003 of the residuals of H1N1 vaccine effectiveness
versus year. Data from Table 1 and Figure 2 in the main text. The slope of the trend line is
−0.0002/year. ANOVA test: H0: slope = 0, F = 0.0021, and p = 0.96. The null hypothesis that
these residuals are independent of time cannot be rejected.
hypothesis that the slope equals zero is not rejected (p = 0.96), as shown in Figure S1. The residuals
of H3N2 vaccine effectiveness (Gupta et al. 2006) were also correlated with the year and the slope
−0.0013/year is not significantly different with zero (p = 0.58), as shown in Figure S2. Therefore
the contribution of other simple time–dependent factors other than pepitope to H1N1 and H3N2
vaccine effectiveness in humans is negligible. Our analysis suggests that the vaccine effectiveness
data in this paper are negligibly affected by these potential biases.
Despite the limited number of available data points in this study, the correlation line between
the pepitope and the vaccine effectiveness has statistical meaning. In Figure 2 in the main text, the
trend line is vaccine effectiveness = −1.19 pepitope + 0.53, the greatest determinant of which is the
data point 1986–87 (b). If this data point is removed, the trend line becomes vaccine effectiveness =
−1.63 pepitope + 0.54, which is not fundamentally distinct with the original trend line. In the data
point 1986–87 (b), the difference of the vaccine effectiveness predicted by these two models is 0.13,
which is roughly one standard error. In reality, most pepitope values are less than 0.1, and so most of
the differences between these two predicted vaccine effectiveness values are less than 0.034, which
is within the noise levels of the epidemiological measurements.
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Figure S2: The linear regression with R2 = 0.018 of the residuals of H3N2 vaccine effectiveness
versus year. Data from (Gupta et al. 2006). The slope of the trend line is −0.0013/year. ANOVA
test: H0: slope = 0, F = 0.32, and p = 0.58. The null hypothesis that these residuals are
independent of time cannot be rejected.
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The basis for calculating pepitope is a set of well defined epitopes. An early definition of the five
epitopes in H1 hemagglutinin (Caton et al. 1982) did not identify numerous amino acid positions in
which mutations were frequently selected in history. These positions are presumably under strong
antigenic pressure to be selected for escape mutation. The more recent definition of H1 epitopes
incorporates these additional amino acid positions as well as amino acids from the epitopes of H3
hemagglutinin (Deem and Pan 2009). Likely additional experiments on the H1 epitopes will allow
further refinement of the calculation of pepitope. Only nine epidemiological data points are available
since the reemergence of H1N1 virus in humans in 1977. The pepitope model parameters may be
further improved as epidemiological data are accumulated.
The antigenic properties are determined by a small number of amino acid substitutions, because
the positions and the amino acids introduced by mutation have distinct effects on the change of
antigenic distance between vaccine strain and dominant circulating strain. For example, mutations
yielding charged amino acids in the dominant epitope are favorable for the virus, and may be the
key amino acid substitution for the antigenic properties (K. Pan et al., submitted). An improved
sequence–based model might assign different amino acid substitutions with weights determined by
the decrease of binding constant between HA and antibody using free energy calculation (K. Pan
and M. W. Deem, submitted). With the current knowledge, the less precise but safe pepitope model
assigns the amino acid substitutions in the dominant epitope with weight one, and assigns other
amino acid substitutions with weight zero. The pepitope model can nevertheless correlate with the
vaccine effectiveness better than the antisera data. That is, for both H1N1 and H3N2, the pepitope
method is superior to other methods in current use.
4 Comparison of the pepitope Model and the HI Assay for
H3N2 Virus
In some cases pepitope model detects antigenic variants better than the HI assay. In the 2003–04
Northern hemisphere flu season, the majority of isolated H3N2 strains were similar to A/Fujian/411/2002
using HI assay (WHO 2004), hence WHO recommended a A/Fujian/411/2002-like strain as the
2004–05 Northern hemisphere H3N2 vaccine component, and A/Wyoming/3/2003 was selected.
Although A/Wyoming/3/2003 is similar to A/Fujian/411/2002 circulating in 2004–05 (”antigeni-
cally equivalent” by HI data (Harper et al. 2004)), the vaccine effectiveness was only moderate
(Gupta et al. 2006). Interestingly, the pepitope between A/Fujian/411/2002 and A/Wyoming/3/2003
was also moderate (pepitope = 0.095), predicting the moderate vaccine effectiveness. In fact, the
pepitope method can also detect antigenic variants more rapidly as they emerge (He and Deem 2010).
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